Oncology biomarker
A molecular signature discovered by applying the Genesis framework to bulk-RNA data plus single-cell RNA-seq replicates. The signature is linked to clinical oncology outcomes and the underlying mechanism has been independently replicated through three orthogonal axes (bulk + single-cell + pathway).
Companion-diagnostic and IVD partnerships are open under mutual NDA. Patent ID, filing stage, and method content are released after NDA execution.
Neurodivergence substrate axes
A variational-basis substrate parametrisation of neurodivergence phenotypes. Maps existing clinical taxonomies onto a low-dimensional axis space, cross-references gene-cluster data and pharmacological response patterns.
Mechanism and parametrisation are under NDA. Companion publications and licensing discussions are routed through the patent layer.
Genesis-based genomic analysis
Applies the Genesis matrix-state framework directly to genomic sequences. A series of experiments has been completed across viral variants and oncology markers.
The analysis pipeline is self-contained and reproducible on a single workstation.
What partners get
Bench-validated mechanism, an IP moat with multiple independent replication axes, and a pipeline that runs on a single workstation. The asset under the hood is a method — made available under mutual NDA to clinical and IVD partners.
cross-references